Last A$0.50 AUD
Change Today +0.01 / 2.04%
Volume 64.3K
As of 12:59 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Open
A$0.50
Previous Close
A$0.49
Day High
A$0.50
Day Low
A$0.49
52 Week High
10/10/13 - A$0.68
52 Week Low
06/14/13 - A$0.30
Market Cap
162.2M
Average Volume 10 Days
190.4K
EPS TTM
A$-0.01
Shares Outstanding
324.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, is engaged in the discovery and development of human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies primarily in Australia. The company’s technologies include HyACT drug delivery technology that enhances the delivery of chemotherapeutic agents to cancer cells; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. It also provides generic fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, the company develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer. It has collaboration with Monash Institute of Pharmaceutical Science to discover drug candidates for G-Protein coupled receptors; and University of Queensland to discover novel opioid analgesics with reduced side effects. The company was founded in 1995 and is headquartered in Brisbane, Australia.

24 Employees
Last Reported Date: 08/30/13
Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Group Financial Controller
Total Annual Compensation: A$153.1K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$226.8K
Vice President of Business Development
Total Annual Compensation: A$184.6K
Vice President of Intellectual Property & Tec...
Total Annual Compensation: A$216.0K
Vice President of Drug Discovery
Total Annual Compensation: A$212.5K
Compensation as of Fiscal Year 2013.

alchemia ltd (ACL) Key Developments

Alchemia Limited Signs License Agreement with Cancer Research Technology

Alchemia Limited entered into an agreement with Cancer Research Technology Limited (CRT) under which Alchemia has in-licensed two early-stage novel anticancer drug candidates (focal adhesion kinase (FAK) inhibitors) from CRT. Under the terms of the agreement, CRT will receive license fees, milestones and royalty payments. The preclinical FAK inhibitors originate from the Australian Cancer Therapeutics CRC (CTx) and will be evaluated by Alchemia in various cancer and cancer stem cell models prior to initiation of formal preclinical and clinical development.

Alchemia Limited Appoints Thomas Liquard as Chief Executive Officer

Alchemia Limited announced the appointment of Thomas Liquard as Chief Executive Officer following the departure of Charles Walker. Mr. Liquard, who joined Alchemia in December 2013 as Chief Operating Officer, brings significant commercial and managerial expertise to the company having most recently served as Senior Director, Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer Inc. in New York.

Alchemia Limited Presents at 26th Annual ROTH Conference, Mar-12-2014 10:00 AM

Alchemia Limited Presents at 26th Annual ROTH Conference, Mar-12-2014 10:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Thomas Liquard, Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.50 AUD +0.01

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies
 

Industry Analysis

ACL

Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit www.alchemia.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.